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Purpose: The gene coding cytochrome P4501B1 (CYP1B1) has been shown to be a major cause of primary congenital
glaucoma in the Iranian population. More recently it was shown to also be important in juvenile-onset open angle glaucoma
(JOAG). We aimed to further investigate the role of CYP1B1 in a larger cohort of primary open angle glaucoma (POAG)
patients which included late-onset patients. We also aimed to set up a microarray based protocol for mutation screening
with an intent of using the protocol in a future population level screening program.
Methods: Sixty three POAG patients, nine affected family members, and thirty three previously genotyped primary
congenital glaucoma (PCG) patients were included in the study. Clinical examination included slit lamp biomicroscopy,
IOP measurement, gonioscopic evaluation, fundus examination, and measurement of perimetry. G61E, R368H, R390H,
and R469W were screened by a protocol that included multiplexed allele specific amplification in the presence of a protease
(PrASE), use of sequence tagged primers, and hybridization to generic arrays on microarray slides. The entire coding
sequences of CYP1B1 and myocilin (MYOC) genes were sequenced in all individuals assessed by the microarray assay
to carry a mutation. Intragenic single nucleotide polymorphism (SNP) haplotpes were determined for mutated alleles.
Results: Genotypes assessed by the array-based PrASE methodology were in 100% concordance with sequencing results.
Seven mutation carrying POAG patients (11.1%) were identified, and their distribution was quite skewed between the
juvenile-onset individuals (5/21) as compared to late-onset cases (2/42). Four of the seven mutation carrying Iranian
patients harbored two mutated alleles. CYP1B1 mutated alleles in Iranian PCG and POAG patients shared common
haplotypes. MYOC mutations were not observed in any of the patients.
Conclusions: The PrASE approach allowed reliable simultaneous genotyping of many individuals. It can be an appropriate
tool for screening common mutations in large sample sizes. The results suggest that CYP1B1 is implicated in POAG
among Iranians, notably in the juvenile-onset form. Contrary to POAG patients studied in other populations, many
mutation harboring Iranian patients carry two mutated alleles. We propose an explanation for this observation.
Glaucoma is a heterogeneous group of optic neuropathies
which manifest by optic nerve head cupping or degeneration
of the optic nerve, resulting in a specific pattern of visual field
loss  [1-3].  The  disease  affects  approximately  65  million
people worldwide and is considered the second leading cause
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of blindness [4]. It is sub-grouped into three major classes on
the basis of etiology, anatomy of the anterior chamber, and
age  of  onset  [2].  Primary  open  angle  glaucoma  (POAG;
OMIM  137760)  accounts  for  70%  of  glaucoma  cases  in
Caucasian populations and usually affects individuals past the
age of 40 [5]. In this form of glaucoma, the anterior chamber
angle and the trabecular meshwork appear normal. POAG is
sometimes divided into the two sub-classes of adult-onset (or
late-onset) and juvenile-onset (JOAG), the latter appearing
between  early  childhood  and  the  age  of  40  [6].  Primary
congenital glaucoma (PCG; OMIM 231300) is characterized
by  an  anatomic  defect  of  the  trabecualr  meshwork
(trabeculodysgenesis) and an age of onset in the neonatal or
infantile period.
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2349Glaucoma  in  some  families  demonstrates  Mendelian
inheritance. Three POAG causing genes have been reported
on the basis of genetic studies on multi-case families. The
three genes code for myocilin (MYOC), optineurin (OPTN),
and  WD  repeat  containing  protein  36  (WDR36)  [6-8].
Mutations in MYOC were the cause of disease in less than 5
percent of POAG patients in various studies [8-10]. Mutations
in OPTN and WDR36 have only rarely been found in POAG
patients  [7,8].  CYP1B1  (OMIM  601771),  encoding
cytochrome P4501B1, is a gene commonly associated with
primary congenital glaucoma. Mutations in CYP1B1 account
for the disease status of 20 to 100% of PCG patients in various
populations [11]. Recently, mutations in CYP1B1 have been
reported in POAG patients [12-16].
The genetic basis of PCG among Iranian patients has been
studied and it was found that nearly 70% of Iranian PCG
patients carry disease associated mutations in CYP1B1 [17].
Although nineteen mutations were observed among the 104
patients studied, four (G61E, R368H, R390H, and R469W)
constituted 76.2% of the mutated CYP1B1 alleles identified.
More recently [13], it was observed that mutations in CYP1B1
accounted for disease status in four probands (17.4%) of a
cohort  of  23  unrelated  Iranians  affected  with  JOAG.  The
mutations observed in the JOAG patients were among the
aforementioned  common  mutations.  The  relatively  large
contribution  of  CYP1B1  to  glaucoma  among  Iranians
suggested by the results of these studies prompted us to further
investigate its role in a larger cohort of POAG patients which
included late-onset patients. We chose to address only the
common mutations with an intent of setting up a neonatal or
population level screening protocol to be used in the future.
The patients were screened for the mutations by a protocol
which  included  a  protease-mediated  allele-specific  primer
extension  (PrASE)  reaction  and  hybridization  to  generic
oligonucleotide tag sequences arrayed onto microarray chips
[18]. Whereas various technologies have been developed to
allow scoring of thousands of sequence variations, the PrASE/
microarray  protocol  is  designed  for  relatively  small  scale
projects wherein far fewer variations are queried in many
samples [19]. The results of our effort are presented.
METHODS
This research was performed in accordance with the Helsinki
Declaration and with the approval of the ethics board of the
International  Institute  of  Genetic  Engineering  and
Biotechnology in Iran. The participants or authorized family
members all consented to participate after being informed of
the  nature  of  the  research.  Sixty  three  unrelated  POAG
patients were recruited from the ophthalmology divisions of
the Hazrat Rasool Hospital (associated with Iran University
of  Medical  Sciences)  and  the  Labbafinejad  Hospital
(associated  with  Shaheed  Beheshti  University  of  Medical
Sciences)  in  Tehran.  The  hospitals  are  national  reference
centers, and patients from throughout Iran are referred to
them. Nine additional affected individuals who were related
to the patients were also included in the study. All patients
were diagnosed to be affected by at least one of the authors
(N.N.  or  S.Y.)  who  are  glaucoma  specialists.  Clinical
examination and criteria for diagnosis were as previously
described  [13].  None  of  the  patients  had  phenotypic
characteristics  suggestive  of  PCG  such  as  megalocornea,
Descemet's  membrane  rupture  (Haab's  striae),  corneal
scarring, or edema. The patients were recruited consecutively
without  regard  to  familial  status  of  disease.  They  were
subsequently queried on the familial status of disease, and
those  who  reported  consanguinity  between  parents  and/or
incidence of disease among relatives were designated familial.
None of the patients nor their family members were included
in our previous studies.
The CYP1B1 mutations addressed by the microarray-
based PrASE protocol were c.182G>A causing p.G61E, c.
1103G>A causing p.R368H, c.1169G>A causing p.R390H,
and  c.1405C>T  causing  p.R469W  (reference  sequences:
NM_000104.2  and  NP_000095.1).  Polymerase  chain
reactions  (PCR)  and  hybridization  onto  chips  were  done
essentially  as  already  described  [18].  Briefly,  a  multiplex
outer PCR reaction was performed on extracted DNA, and one
microliter of this reaction was used as template for a multiplex
nested PCR. Subsequently, the inner PCR amplicons served
as  template  in  a  PrASE  reaction  in  which  extension  of
mismatched primers was made unlikely by inclusion of a
protease  that  degrades  the  DNA  polymerase.  Two  allele
specific  primers  for  each  of  the  four  mutation  sites  were
present in the PrASE reaction, and each of the eight primers
contained at its 5′ end a unique sequence complementary to
one of the tag oligonucleotides on a generic tag-array. Cy3
labeled dNTPs were also present which allowed fluorescence
detection.  The  products  of  the  PrASE  reaction  were
hybridized  to  tag-spotted  microarrays.  Spotting  was  done
using the VersArray ChipWriter (Bio-Rad, Milan, Italy). Each
microarray  slide  was  spotted  with  48  arrays  of  30  tag
oligonucleotides  in  triplicate  (array  on  array).  Prior  to
hybridization, the arrays on each slide were placed into 48
compartments with a home-made silicon rubber mask, and
each compartment was used to assess the genotypes of one
individual  at  the  four  mutation  sites.  Eight  of  the  tag
oligonucleotides  were  devoted  to  the  present  analysis.
Fluorescence  binding  to  the  spots  was  detected  using
VersArray ChipReader (Bio-Rad). Fluorescence signals were
measured with the GenePix 5.0 (Medical Devices, Sunnyvale,
CA) image analysis software and the allelic fraction (AF) for
each individual at each mutation site was calculated. AF is
defined as intensity from the normal allele divided by sum of
intensities from both alleles. A cluster diagram for each site
was created by plotting the AFs of all individuals at that site
against the logarithm of the sum of both his signals at that site.
If AF values of multiple individuals are well clustered into
groups with values approaching zero, one, and an intermediate
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2350value,  genotypes  of  individuals  in  those  clusters  can  be
designated,  respectively,  homozygous  for  mutant  allele,
homozygous  for  normal  allele,  and  heterozygous.  The
genotype of each individual at each position was called on the
basis of his position in the respective cluster diagram. The
sequences of all primers used in the PCR and PrASE reactions
are presented in Table 1.
Coding exons 2 and 3 of CYP1B1 of all individuals called
heterozygous or homozygous at any of the four mutation
positions were sequenced by the di-deoxy terminator protocol
as previously reported [13]. These exons were also sequenced
in  four  randomly  chosen  patients  without  mutations.
Sequencing was done to confirm the genotype calls, identify
possible  second  mutations  in  the  gene,  and  to  ascertain
intragenic SNP haplotypes associated with the mutant alleles
[17]. Additionally, the three exons of MYOC were sequenced
in all individuals carrying one or two CYP1B1 mutated alleles
as already described [13]. This was done to identify patients
who may have carried mutations in both genes [14,20,21].
Intragenic CYP1B1 and MYOC SNP haplotypes of patients
carrying CYP1B1 mutated alleles were ascertained using the
PHASE 2.0 software [22,23].
RESULTS
The clinical features of the patients are presented in Table 2.
Average age at diagnosis of the patients was 50.3 years old.
Age at diagnosis of 21 of the 63 pateints (33.3%) ranged
between 6 years and 38 years (average 25.5 years), and these
patients were classified as juvenile-onset POAG cases. The
average age at diagnosis of the late-onset cases was 62.7 years
old. As the patients were recruited without regard to age, a
notable fraction, possibly one third, of Iranian POAG patients
may have juvenile onset. The heredity status of glaucoma of
six of the patients was unknown. Of the remaining 57 patients,
39 (68%) were familial and 18 (32%) were sporadic. The
fraction of juvenile and late onset POAG patients who were
familial was approximately equal. Two pedigrees in which
inheritance was familial are presented in Figure 1.
In addition to the sixty three patients and nine affected
relatives, thirty three PCG patients known by sequencing from
our previous studies to carry the mutations in the heterozygous
or homozygous states were included in the PrASE/microarray
analysis  to  enable  formation  of  stronger  clusters  [17].
Therefore, 420 genotypes (genotypes of 105 individuals at 4
variant nucleotide sites) were queried by the protocol. The
clusters for the four mutations are presented in Figure 2. The
TABLE 1. PRIMER SEQUENCES.
Name Sequence Product size
Multiplex outer PCR
primers
CYP1B1-G61E-out F 5′-CGAGCGAACGAGAGGTGAG-3′ 141 bp
CYP1B1-G61E-out R 5′-GCTGGCCACTGTGCATGTG-3′
CYP1B1-R368H &
R390H-out F
5′-GTGCAGGCAGAATTGGATCAG-3′ 155 bp
CYP1B1-R368H &
R390H-out R
5′-GTGTTGGCAGTGGTGGCATG-3′
CYP1B1-R469W-out F 5′-GATCCAGCTCGATTCTTGGAC-3′ 148 bp
CYP1B1-R469W-out R 5′-GGTGAGCCAGGATGGAGATG-3′
Multiplex inner PCR
primers*
CYP1B1-G61E-In F 5′-CACTGCTTCGCAGGCTGACGTTACTGGCCCACCGCCGCCGCGT-3′ 73 bp
CYP1B1-G61E-In R 5′-CGGGCCCGTTTGCGTGGCC-3′
CYP1B1-R368H-In F 5′-CACTGCTTCGCAGGCTGACGTTACTATCAGGTCGTGGGGAGGGAC-3′ 76 bp
CYP1B1-R368H-In R 5′-GGTTGGGCTGGTCACCCATAC-3′
CYP1B1-R390H-In F 5′-CACTGCTTCGCAGGCTGACGTTACTCTGGCCTTCCTTTATGAAGCCA-3′ 83 bp
CYP1B1-R390H-In R 5′-GAGGAATAGTGACAGGCACAAAG-3′
CYP1B1-R469W-In F 5′-CACTGCTTCGCAGGCTGACGTTACTAGTGATGATTTTTTCAGTGGGCAA-3′ 86 bp
CYP1B1-R469W-In R 5′-CTGCATCTTAGAAAGTTCTTCGC-3′
Biotinylatad inner
primer*
5′- CACTGCTTCGCAGGCTGACGTTACT-3′
PrASE primers¶
CYP1B1-G61E-T22-G 5′-TTACCTATGATTGATCGTGGTGATATCCGTTTGCGTGGCCACTGATCGG-3′
CYP1B1-G61E-T23-A 5′-GCTGTGGCATTGCAGCAGATTAAGGTTTGCGTGGCCACTGATCGA-3′
CYP1B1-R368H-T24-G 5′-TGACGTCATTGTAGGCGGAGAGCTAGTCACCCATACAAGGCAGAC-3′
CYP1B1-R368H-T25-A 5′-TCAATAATCAACGTAAGGCGTTCCTGTCACCCATACAAGGCAGAT-3′
CYP1B1-R390H-T26-G 5′-TTATCGGCTACATCGGTACTGACTCAGGCACAAAGCTGGAGAAGC-3′
CYP1B1-R390H-T27-A 5′-CCATTATCGCCTGGTTCATTCGTGAAGGCACAAAGCTGGAGAAGT-3′
CYP1B1-R469W-T28-C 5′-GGCGTACCTTCGCGGCAGATATAATAGTTCTTCGCCAATGCACCG-3′
CYP1B1-R469W-T29-T 5′-AACTGAGCCGTAGCCACTGTCTGTCCAGTTCTTCGCCAATGCACCA-3′
* Common sequence at 5´-termini of inner PCR forward primers and the biotinylated form of the same sequence are italicized.
The biotinylated primer was included in the inner PCR reaction to allow capture of PCR products onto strepavidin coated beads
before the PrASE reaction. ¶ 5´-termini sequences of PrASE primers complementary to the tag sequences on the arrays are
underlined.
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ethree  possible  genotypes  of  all  the  mutations  are  well
clustered, suggesting that genotype calls can be made with
confidence. The genotypes of the individuals as ascertained
in the clusters could in all cases have been called by visual
inspection  of  the  fluorescence  intensities  on  the  arrays.
Hybridizations on replicate spots were almost identical. All
heterozygous and homozygous mutant genotype calls, and
absence of the mutations in four individuals were confirmed
by sequencing.
We identified mutations in three of the four screened
positions. These mutations were found in seven (11.1%) of
the 63 patients screened (Table 2). R469W was not observed
in any of the patients. One heterozygous carrier of R368H (JG-
R-226) was observed to also carry an E229K mutated allele
upon sequencing. This mutation has previously been reported
to  be  associated  with  PCG  and  POAG  [12,15-17,24].  No
additional disease associated mutation was observed in the
remaining patients by sequencing. Both alleles were mutated
in four of the seven patients harboring CYP1B1 mutations, and
only one allele was mutated in the remaining three. G61E, the
most frequent mutated CYP1B1 allele among Iranian PCG
patients,  was  also  the  most  frequently  observed  mutation
among the POAG patients. The JOAG affected sibling of two
of the JOAG patients (JG-R-226 and JG-M-4) had the same
genotype  as  the  respective  proband.  The  haplotypes
associated  with  most  mutations  observed  in  the  POAG
patients,  as  defined  by  six  intragenic  single  nucleotide
polymorphisms (SNPs), were the same as previously found to
be associated with the same mutations in PCG patients of Iran
and other populations (Table 2) [17]. The only exception was
the E229K allele identified by sequencing. Multiple origins
for this mutation in human history have been suggested based
on  haplotype  data  [17,20].  A  disease  associated  MYOC
mutation was not observed in any of the patients carrying
CYP1B1 mutations. MYOC haplotypes in the patients defined
by  three  common  intragenic  SNPs  were  the  same  as
previously observed among Iranians (Table 2) [13].
DISCUSSION
Although  the  microarray-based  PrASE  protocol  has  been
previously introduced as a technology alternative to direct
sequencing,  this  work  represents  its  first  implementation
designed  to  address  a  biological  question  [18,19,25].  The
genotypes called were reproducible and in 100% concordance
with sequencing data. We believe it is an appropriate tool for
screening  common  mutations  in  large  sample  sizes,  for
example to obtain epidemiological data on carrier frequencies
or prevalence rates. Our protocol can easily be upgraded to
simultaneously  screen  a  larger  number  of  mutations.
Multiplexing the PrASE reaction for up to 75 SNPs has been
reported [25,26]. The use of microarray slides spotted with
generic tag oligonucleotides allows the flexibility of using the
same slides for querying mutations in different genes.
We surmise the CYP1B1 mutations common in Iranian
PCG patients may be associated with disease status in 11.1%
of the Iranian POAG patients in our cohort. Five of the patients
who  carried  disease  associated  CYP1B1  mutations  were
among the 21 juvenile-onset (JOAG) subgroup, a proportion
(23.8%) similar to the proportion we recently reported for an
independent cohort of Iranian JOAG patients (17.4%) [13].
Two of the patients who carried disease associated CYP1B1
mutations were among the 42 of the late-onset group (4.8%).
The  difference  in  proportion  of  JOAG  patients  (9/44;
including  patients  of  reference  14)  and  late  onset  POAG
patients (2/42) is statistically significant (p=0.03). A similar
trend on the role of CYP1B1 in JOAG and late onset POAG
is revealed upon analysis of data presented in two previous
studies  which  included  both  juvenile  and  late-onset  cases
[12,16]. These observations suggest that in addition to the
significant role that CYP1B1 has in PCG, it may also have
roles in juvenile and late-onset POAG and that its role in
JOAG may be more notable than its role in late-onset POAG.
The haplotype analysis presented here show that identical
mutated CYP1B1 alleles may be involved in the etiology of
the various forms of glaucoma, suggesting that other genetic
and/or environmental factors can affect the course of disease
development.
In  three  studies  on  the  role  of  CYP1B1  in  POAG  of
patients from various populations excluding the studies on
Iranian patients, 29 of 518 patients (5.6%) were reported to
carry mutations in the gene [12,15,16]. Among the 29 patients,
Figure  1.  Familial  POAG  pedigrees.
Probands are indicated with arrows. A:
Pedigree JG-M-4; the age at onset of the
two  affected  siblings  was  24  and  25
years.  Both  carried  homozygous
CYP1B1  mutations.  B:  Pedigree  LG-
R-213;  the  age  at  onset  of  the  three
affected individuals was 60–68 years.
CYP1B1 mutations were not observed in
the proband of this pedigree.
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2353only three carried two mutated alleles. The results at first
appearance seem to be in contrast to the findings on the Iranian
population wherein eight of the eleven POAG patients with
CYP1B1  mutations  carried  two  mutated  alleles  [13  and
present study]. However, it is possible that this discordance is
due to the combined effects of difference in role of CYP1B1
mutations  in  juvenile-onset  and  late-onset  POAG,  and
difference in proportions of these classes of patients in the
populations.  In  fact,  The  Genetics  Home  Reference  site,
sponsored by the US National Library of Medicine, states that
juvenile  open  angle  glaucoma  affects  about  1  in  50,000
people,  whereas  open  angle  glaucoma  affects  about  one
percent of individuals past the age of 40 years. Our patient
recruitment  suggests  that  a  notably  higher  proportion,
possibly one third, of Iranian POAG cases may be juvenile-
onset  cases  (see  results).  We  suggest  that  harboring  two
mutated CYP1B1 alleles will most likely result in the PCG
phenotype.  If  genetic  background  and/or  environmental
factors  preclude  this  outcome,  the  POAG  phenotype  may
arise, most likely the juvenile form. All eight Iranian POAG
patients  carrying  two  mutated  alleles  were  juvenile-onset
cases, whereas only one patient with a single mutated allele
was juvenile onset. Similarly, age at diagnosis of two of the
three  patients  in  the  other  populations  who  carried  two
mutated  alleles  was  13  and  18  years  [12,16].  Individuals
carrying one mutated CYP1B1 allele may be asymptomatic or
only mildly symptomatic. If they develop glaucoma, it is more
likely that they develop late-onset POAG rather than the more
severe congenital or even juvenile forms of glaucoma.
In  Western  populations  wherein  consanguineous
marriages are rare and in populations wherein CYP1B1 is a
cause of PCG in a relatively low percent of patients, possibly
indicating low frequency of CYP1B1 mutated alleles in those
populations, individuals who carry two mutated alleles will
be correspondingly few and most of these will develop PCG.
It will be more likely to identify POAG patients with one
rather than two mutated alleles in these populations. However,
in a population like Iran wherein extensive inbreeding exists
and wherein mutated CYP1B1 alleles may be frequent, there
are  expected  to  be  a  larger  number  of  patients  with  two
mutated CYP1B1 alleles who do not develop PCG and proceed
to develop POAG at a later age. The heteorozygotes are likely
to have milder symptoms and remain undiagnosed. These
considerations  may  explain  why  autosomal  recessive
inheritance for JOAG and JOAG/PCG mixed pedigrees are
often observed in the Iranian population [13]. They may also
shed light on the pathogenic effects of CYP1B1 mutations. It
will  be  of  interest  to  learn  the  CYP1B1  genotypes  and
inheritance pattern of JOAG in other populations with high
rates of consanguineous marriages and high frequencies of
mutated CYP1B1 alleles.
We conclude that CYP1B1 is important in the etiology of
POAG,  particularly  the  juvenile  form,  in  the  Iranian
population.  Incomplete  penetrance  for  CYP1B1  mutations
with regard to PCG has been well documented [27]. However
the results of the present study suggest that long-term follow
up of unaffected individuals with an affected genotype may
result in diagnosis of juvenile or late onset POAG. As all forms
of  glaucoma  are  devastating  diseases  which  may  lead  to
blindness  and  have  notable  social  and  economic
consequences, it is recommended that the gene be screened
for mutations in individuals at risk, and that phenotypically
affected and unaffected individuals carrying mutated alleles
be kept under medical surveillance.
Figure 2. Results of microarray-based
PrASE genotypings. Cluster diagrams
of genotyping results of 105 individuals
for four common CYP1B1 mutations are
shown.  Red  squares:  PCG  patients
whose genotypes were known because
of  previous  direct  sequencing.  Blue
squares:  POAG  patients  whose
genotypes  were  determined  by  the
PrASE/hybridization reactions.
Molecular Vision 2008; 14:2349-2356 <http://www.molvis.org/molvis/v14/a271> © 2008 Molecular Vision
2354ACKNOWLEDGMENTS
We thank the patients and family members for participating
in the study. This research was funded by grant number 250
of  the  National  Institute  of  Genetic  Engineering  and
Biotechnology.
REFERENCES
1. Fan BJ, Wang DY, Lam DS, Pang CP. Gene mapping for
primary  open  angle  glaucoma.  Clin  Biochem  2006;
39:249-58. [PMID: 16332362]
2. Ray K, Mukhopadhyay A, Acharya M. Recent advances in
molecular genetics of glaucoma. Mol Cell Biochem 2003;
253:223-31. [PMID: 14619973]
3. Sarfarazi  M.  Recent  advances  in  molecular  genetics  of
glaucomas.  Hum  Mol  Genet  1997;  6:1667-77.  [PMID:
9300658]
4. Quigley HA. Number of people with glaucoma worldwide. Br
J Ophthalmol 1996; 80:389-93. [PMID: 8695555]
5. Shields MB, Ritch R, Krupin T. Classification of the glaucomas.
In: Ritch R, Shields MB, Krupin T, editors. The Glaucomas.
St. Louis (MO):Mosby-Year Book. 1996. p 717–25.
6. Stone EM, Fingert JH, Alward WLM, Nguyen TD, Polansky
JR, Sunden SLF, Nishimura D, Clark AF, Nystuen A, Nichols
BE, Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield
VC. Identification of a gene that causes primary open angle
glaucoma. Science 1997; 275:668-70. [PMID: 9005853]
7. Monemi S, Spaeth G, DaSilva A, DaSilva G, Popinchalk S,
Ilitchev E, Liebmann J, Ritch R, Heon E, Crick RP, Child A,
Sarfarazi M. Identification of a novel adult-onset primary
open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol
Genet 2005; 14:725-33. [PMID: 15677485]
8. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados
M,  Heon  E,  Krupin  T,  Ritch  R,  Kreutzer  D,  Crick  RP,
Sarfarazi  M.  Adult-onset  primary  open  angle  glaucoma
caused  by  mutations  in  optineurin.  Science  2002;
295:1077-9. [PMID: 11834836]
9. Aldred  MA,  Baumber  L,  Hill  A,  Schwalbe  EC,  Goh  K,
Karwatowski W, Trembath RC. Low prevalence of MYOC
mutations in UK primary open-angle glaucoma patients limits
the utility of genetic testing. Hum Genet 2004; 115:428-31.
[PMID: 15338275]
10. Fingert JH, Héon E, Liebmann JM, Yamamoto T, Craig JE, Rait
J, Kawase K, Hoh S-T, Buys YM, Dickinson J, Hockey RR,
Williams-Lynn D, Trope G, Kitazawa Y, Ritch R, Mackey
DA, Alward WLM, Sheffield VC, Stone EM. Analysis of
myocilin  mutations  in  1703  glaucoma  patients  from  five
different  populations.  Hum  Mol  Genet  1999;  8:899-905.
[PMID: 10196380]
11. Sarfarazi  M,  Stoilov  I,  Schenkman  J.  Geneticsa  and
biochemistry of primary congenital glaucoma. Ophthalmol
Clin North Am 2003; 16:543-54. [PMID: 14740995]
12. Acharya M, Mookherjee S, Bhattacharjee A, Bandyopadhyay
A, Daulat Thakur SK, Bhaduri G, Sen A, Ray K. Primary role
of CYP1B1 in Indian juvenile-onset POAG patients. Mol Vis
2006; 12:399-404. [PMID: 16688110]
13. Bayat B, Yazdani S, Alavi A, Chiani M, Chitsazian F, Tusi BK,
Suri F, Narooie-Nejhad M, Sanati MH, Elahi E. Contributions
of MYOC and CYP1B1 mutations to JOAG. Mol Vis 2008;
14:508-17. [PMID: 18385784]
14. Chakrabarti S, Kaur K, Komatireddy S, Acharya M, Devi K,
Mukhopadhyay A, Mandal AK, Hasnain SE, Chandrasekhar
G, Thomas R, Ray K. Gln48His is the prevalent myocilin
mutation  in  primary  open  angle  and  primary  congenital
glaucoma  phenotypes  in  India.  Mol  Vis  2005;  11:111-3.
[PMID: 15723004]
15. López-Garrido M-P, Sánchez-Sánchez F, López-Martínez F,
Aroca-Aguilar  J-D,  Blanco-Marchite  C,  Coca-Prados  M.
Heterozygous CYP1B1 gene mutations in Spanish patients
with  primary  open-angle  glaucoma.  Mol  Vis  2006;
12:748-55. [PMID: 16862072]
16. Melki R, Colomb E, Lefort N, Brézin A, Garchon H. CYP1B1
mutations in French patients with early-onset primary open-
angle  glaucoma.  J  Med  Genet  2004;  41:647-51.  [PMID:
15342693]
17. Chitsazian F, Tusi BK, Elahi E, Saroei HA, Sanati M, Yazdani
S, Pakravan M, Nilforooshan N, Eslami Y, Mehrjerdi MA,
Zareei R, Jabbarvand M, Abdolahi A, Lasheyee AR, Etemadi
A, Bayat B, Sadeghi M, Banoei MM, Ghafarzadeh B, Rohani
MR, Rismanchian A, Thorstenson Y, Sarfaraz M. CYP1B1
mutation  profile  of  Iranian  primary  congenital  glaucoma
patients  and  associated  haplotypes.  J  Mol  Diagn  2007;
9:382-93. [PMID: 17591938]
18. Hultin E, Käller M, Ahmadian A, Lundeberg J. Competitive
enzymatic  reaction  to  control  allele-specific  extensions.
Nucleic Acids Res 2005; 33:e48. [PMID: 15767273]
19. Käller M, Hultin E, Holmberg K, Persson M-L, Odeberg J,
Lundeberg  J,  Ahmadian  A.  Comparison  of  PrASE  and
Pyrosequencing for SNP Genotyping. BMC Genomics 2006;
7:291. [PMID: 17107626]
20. Kaur K, Reddy A, Mukhopadhyay A, Mandal A, Hasnain S,
Ray  K,  Thomas  R,  Balasubramanian  D,  Chakrabarti  S.
Myocilin gene implicated in primary congenital glaucoma.
Clin Genet 2005; 67:335-40. [PMID: 15733270]
21. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M,
Trope G, Williams-Lyn D, Heon E. Digenic inheritance of
early-onset glaucoma: Cyp1b1, a potential modifier gene. Am
J Hum Genet 2002; 70:448-60. [PMID: 11774072]
22. Stephens M, Donnelly P. A comparision of Bayesian methods
for haplotype reconstruction from population genotype data.
Am J Hum Genet 2003; 73:1162-9. [PMID: 14574645]
23. Stephens M, Smith N, Donnelly P. A new statistical method for
haplotype reconstruction from population genotype data. Am
J Hum Genet 2001; 68:978-89. [PMID: 11254454]
24. Colomb E, Kaplan J, Garchon H-J. Novel cytochrome P450 1B1
(CYP1B1)  mutations  in  patients  with  primary  congenital
glaucoma  in  France.  Hum  Mutat  2003;  22:496.  [PMID:
14635112]
25. Käller M, Tuominen R, Ahmadian A, Magnusson V, Egyhazi
S,  Hansson  J,  Lundeberg  J.  Detection  of  MC1R
Polymorphisms  with  Protease-Mediated  Allele-Specific
Extension as an Alternative to Direct Sequencing. Clin Chem
2005; 51:2388-91. [PMID: 16306106]
26. Pettersson E, Lindskog M, Lundeberg J, Ahmadian A. Tri-
nucleotide  threading  for  parallel  amplification  of  minute
amounts  of  genomic  DNA.  Nucleic  Acids  Res  2006;
34:e49. [PMID: 16582098]
27. Bejjani BA, Stockton DW, Lewis RA, Tomey KF, Dueker DK,
Jabak M, Astle WF, Lupski JR. Multiple CYP1B1 mutations
and incomplete penetrance in inbred population segregating
Molecular Vision 2008; 14:2349-2356 <http://www.molvis.org/molvis/v14/a271> © 2008 Molecular Vision
2355primary congenital glaucoma suggest frequent de novo events
and  a  dominant  modifier  locus.  Hum  Mol  Genet  2000;
9:367-74. [PMID: 10655546]
Molecular Vision 2008; 14:2349-2356 <http://www.molvis.org/molvis/v14/a271> © 2008 Molecular Vision
The print version of this article was created on 10 December 2008. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
2356